PharVision Advisers’s Santander BSBR Stock Holding History

PharVision Advisers’s Portfolio BSBR Stock Details BSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,107	Closed	-$77.7K	–	73
2026 Q1	$77.7K	Buy	+13,107	New	+$83.4K	0.79%	68

Other funds holding BSBR

Banco Santander Madrid, Spain $16.1B AUM 35.02% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PharVision Advisers's BSBR Position: Q2 2026 in Review

PharVision Advisers sold out of Santander (BSBR) in Q2 2026, closing a stake of 13,107 shares — an estimated $77.7K sold.

PharVision Advisers first reported a position in BSBR in Q1 2026 and held it in 1 quarter. The position peaked at $77.7K in Q1 2026. 89 funds tracked by Wall St. Rank hold BSBR as of Q2 2026.

PharVision Advisers reported no remaining Santander position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 13,107 Santander shares in Q2 2026, an estimated $77.7K.
PharVision Advisers first reported a position in Santander in Q1 2026 and held it in 1 quarter.
PharVision Advisers's Santander position peaked at $77.7K in Q1 2026.
89 funds tracked by Wall St. Rank held Santander as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.